In mice, it has been shown that IL-17 RA signaling significantly contributes to renal tissue injury in experimental autoimmune glomerulonephritis and blocking IL-17 RA may be a promising therapeutic strategy for the treatment of proliferative and crescentic glomerulonephritis [139]. Here, IL17A is linked to crescentic glomerulonephritis.